Table 2.
Periprosthetic bone mineral density and bone-implant shear strength of the groups with the mean and median values after 12 weeks (4 weeks before and 8 weeks after implantation) treatment
| Bone mineral density (g/cm2) | Bone-implant shear strength (N) | |||
|---|---|---|---|---|
| Mean | Median | Mean | Median | |
| Control | 0.250 ± 0.019 | 0.249 (0.229–0.278) | 6.99 ± 0.76 | 6.98 (5.89–8.11) |
| Alendronate | 0.381 ± 0.022 | 0.384 (0.346–0.409) | 9.65 ± 1.07 | 9.77 (8.12–11.23) |
| Risedronate | 0.372 ± 0.028 | 0.370 (0.332–0.411) | 9.69 ± 1.13 | 9.84 (8.02–11.23) |
| Salmon calcitonin | 0.302 ± 0.030 | 0.294 (0.276–0.356) | 9.27 ± 1.15 | 9.00 (7.71–10.98) |
| Indomethacine | 0.203 ± 0.019 | 0.198 (0.181–0.231) | 5.14 ± 0.69 | 5.17 (4.12–6.13) |
The values are given as the mean ± SD and the median with the minimum-maximum values in parentheses